Advertisement


James O. Armitage, MD, on Advanced Hodgkin Lymphoma: Choosing Among BEACOPP, A-AVD, and Checkpoint Inhibitors

2021 Pan Pacific Lymphoma Conference

Advertisement

James O. Armitage, MD, of the University of Nebraska Medical Center, discusses various treatment regimens for patients with Hodgkin lymphoma, including BEACOPP, brentuximab vedotin, ABVD, A-AVD, nivolumab, and pembrolizumab—and the factors to consider when choosing among them.



Related Videos

Lymphoma
Immunotherapy

Alison J. Moskowitz, MD, on ABVD in Hodgkin Lymphoma: Adding Brentuximab Vedotin and Checkpoint Inhibitors to Standard Treatment

Alison J. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses the combination ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), individualized approaches for treating patients with Hodgkin lymphoma, and novel methods for risk stratification.

Multiple Myeloma

Nina Shah, MD, on Newly Diagnosed Multiple Myeloma: Novel Combination Therapies

Nina Shah, MD, of the University of California, San Francisco, discusses triplet drug combinations that are the current standard of care for transplant-eligible and -ineligible patients with multiple myeloma, as well as quadruplet therapies that demonstrate depth of response in newly diagnosed cases, where they may become the standard of care along with transplantation and maintenance treatments.

Lymphoma

Andrew D. Zelenetz, MD, PhD, on MRD Testing in the Management of Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the role of minimal residual disease evaluation in the treatment of non-Hodgkin lymphoma, techniques used to predict relapse such as immunosequencing and CAPP-Sequencing, and whether such assays could replace the use of imaging with its attendant radiation exposure.

Multiple Myeloma

Muhamed Baljevic, MD, on Multiple Myeloma: Review of Novel Management Strategies

Muhamed Baljevic, MD, of the University of Nebraska Medical Center, reviews the outlook for treating patients with relapsed and refractory multiple myeloma, the rapidly expanding array of therapeutic options with novel mechanisms of action, and the challenges of sequencing treatments.

Lymphoma

Sonali M. Smith, MD: Can CNS Prophylaxis Prevent Secondary High-Grade B-Cell Lymphomas?

Sonali M. Smith, MD, of the University of Chicago, discusses the many uncertainties in preventing secondary high-grade B-cell lymphomas, which have a poor prognosis; how to discern the patients at highest risk; and whether prophylaxis with monoclonal antibodies such as rituximab can mitigate the likelihood of secondary lymphoma.

Advertisement

Advertisement




Advertisement